Acute promyelocytic leukemia: a curable disease (original) (raw)

Leukemia volume 12, pages 1866–1880 (1998)Cite this article

Abstract

The Second International Symposium on Acute Promyelocytic Leukemia (APL) was held in Rome in 12–14 November 1997. Clinical and basic investigators had the opportunity to discuss in this meeting the important advances in the biology and treatment of this disease achieved in the last 4 years, since the First Roman Symposium was held in 1993. The first part of the meeting was dedicated to relevant aspects of laboratory research, and included the following topics: molecular mechanisms of leukemogenesis and of response/resistance to retinoids, biologic and therapeutic effects of new agents such as arsenicals and novel synthetic retinoids; characterization of APL heterogeneity at the morphological, cytogenetic and immunophenotypic level. The updated results of large cooperative clinical trials using variable combinations of all-trans retinoic acid (ATRA) and chemotherapy were presented by the respective group chairmen, and formed the ‘core’ part of the meeting. These studies, which in most cases integrated the molecular assessment of response to treatment, provided a stimulating framework for an intense debate on the most appropriate front-line treatment options to be adopted in the future. The last day was dedicated to special entities such as APL in the elderly and in the child, as well as the role of bone marrow transplantation. The prognostic value of molecular monitoring studies was also discussed in the final session of the meeting. In this article, we review the major advances and controversial issues in APL biology and treatment discussed in this symposium and emerging from very recent publications. We would like to credit the successful outcome of this meeting to the active and generous input of all invited speakers and to participants from all over the world who provided constructive and fruitful discussions.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Cellular Biotechnology and Hematology, University ‘La Sapienza’, Rome, Italy
    F Lo Coco, G Avvisati & F Mandelli
  2. Department of Histology and Medical Embryology, University ‘La Sapienza’, Rome, Italy
    C Nervi

Authors

  1. F Lo Coco
    You can also search for this author inPubMed Google Scholar
  2. C Nervi
    You can also search for this author inPubMed Google Scholar
  3. G Avvisati
    You can also search for this author inPubMed Google Scholar
  4. F Mandelli
    You can also search for this author inPubMed Google Scholar

Additional information

This Review is also a Meeting Report as it is based on an extension and updating of the literature relating to the data presented at the Second International Symposium on APL (Acute Promyelocytic Leukemia: A Curable Disease), Rome, 12–14 November 1997 (Chairman: Professor Franco Mandelli).

Rights and permissions

About this article

Cite this article

Coco, F., Nervi, C., Avvisati, G. et al. Acute promyelocytic leukemia: a curable disease.Leukemia 12, 1866–1880 (1998). https://doi.org/10.1038/sj.leu.2401230

Download citation

Keywords

This article is cited by